Skip to content

This healthcare tech stock could completely change cancer treatment


We don't often get really excited by a company, but in this case we think there is a short term window of opportunity for investors with this Canadian-listed company before regulatory approvals make it much more widely visible, both to the medical community and to fund managers.

We have been tipping healthcare stocks on a regular basis for our Armchair Trader Plus+ subscribers recently. This is largely because it is a sector that continues to shine even during periods of economic stagnation. Well-positioned companies like this one with an experienced leadership team that has a long track record in the space are able to perform well, especially in the US healthcare market.

In this case we have bought into a stock that has developed a revolutionary, AI-driven post-operative solution for breast cancer sufferers. We bought at CAD 1.92 and have added it to our Venture Portfolio.

Shares have had a good run recently, but we anticipate regulatory approvals of the technology, which is already in use in US hospitals, will take it higher. Stock was trading at 1.15 Canadian dollars in November, and is now around 1.9. We think it could easily make 4.5 to even five bucks. It looks as if it is also available on the main UK share trading platforms.

Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top